KOSDAQBiotech & Pharma086900

Medy-Tox

₩68,900▼ 2.13%2026-11-18 close
Market Cap
₩502.9B
Turnover
₩900M
Volume
10K
Shares out.
7.3M
PER
24.1×
PBR
1.2×
EPS
₩2,965
Dividend Yield
1.68%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩1,200 per share · Prices as of the 2026-11-18 close

01

Report overview

Medy-Tox: Overseas toxin growth and cost gains lift profit

Medy-Tox's Q3 2026 operating profit rose 74.5% year on year even as revenue fell 2.8%. Overseas botulinum toxin growth and lower cost and SG&A ratios drove the gain, while toxin concentration and litigation costs remain the key variables to watch.

  1. 1

    Q3 2026 revenue was KRW 59.3 billion, down 2.8% year on year, while operating profit rose 74.5% to KRW 15.5 billion. Lower cost of sales and SG&A expenses drove the profit gain.

  2. 2

    Overseas toxin sales rose 17% year on year to KRW 20.9 billion, while domestic toxin sales fell 17% to KRW 14.6 billion. Overseas growth offset the domestic decline, keeping total botulinum toxin sales at KRW 35.5 billion, close to the prior-year level.

  3. 3

    FY2025 revenue reached KRW 247.3 billion, rising for three consecutive years from 2023, but operating profit fell 16.4% to KRW 17 billion. The operating margin narrowed to 6.9%.

  4. 4

    Medy-Tox's IR material shows an adjusted operating margin excluding legal costs of 33% in Q3, up from 29% in the prior quarter. Legal expenses remain a significant variable for profitability.

  5. 5

    Filler sales declined temporarily due to the restructuring of global sales channels. Local supply of two Neuramis products, which received Chinese approval, is scheduled to ramp up from Q4 2026.

02

Business structure

Medy-Tox is a biotech and aesthetics company centered on botulinum toxin products and hyaluronic acid fillers. Toxins are the core of its earnings, and their share of Q1 2026 sales was 62%, up from 51% a year earlier.

The filler share is smaller, and filler sales declined temporarily in Q3 2026 due to the restructuring of global sales channels. In Korea, the premium toxin Coretox continues to sell steadily, but domestic toxin sales in Q3 2026 fell 17% year on year to KRW 14.6 billion, partly because some shipments moved into Q4.

Overseas, the company runs a dual-brand strategy pairing Meditoxin with its affiliate's next-generation toxin Neulux, and overseas toxin sales rose 17% to KRW 20.9 billion in the same quarter. Reports cited growth in Brazil, Thailand and Saudi Arabia.

The domestic fat-reduction injection Newbizu, a 40th domestic new drug, has gained traction quickly and reached its 2026 annual sales target early. Health functional food and cosmetics, the other business lines, generated KRW 7.5 billion in Q1 2026 sales, or 12.4% of the total. On the competitive front, litigation with Hugel and Daewoong Pharmaceutical continues.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩61B₩8.9B14.6%
2025Q4₩60.7B-₩3.7B−6.1%
2026Q1₩60.7B₩7.4B12.1%
2026Q2₩68.7B₩4.8B6.9%
2026Q3₩59.3B₩15.5B26.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩195.1B₩46.7B₩37B23.9%8.6%37.5%
2023₩221.1B₩17.3B₩9.8B7.8%2.1%28.9%
2024₩228.6B₩20.3B₩17B8.9%3.6%30.7%
2025₩247.3B₩17B₩16.6B6.9%3.7%28.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual results show diverging trends between growth in sales and a slowdown in profitability. Revenue went from KRW 195.1 billion in 2022 to KRW 221.1 billion in 2023 (up 13.3%), KRW 228.6 billion in 2024 (up 3.4%) and KRW 247.3 billion in 2025 (up 8.2%), rising for three consecutive years from 2023.

Media reported that 2025 revenue was a record for three straight years. Operating profit peaked at KRW 46.7 billion in 2022 (margin 23.9%), fell to KRW 17.3 billion in 2023 (down 62.9%), recovered to KRW 20.3 billion in 2024 (up 17.5%), and dropped again to KRW 17 billion in 2025 (down 16.4%), with the margin at 6.9%.

Profit attributable to controlling shareholders went from KRW 37 billion in 2022 to KRW 9.76 billion in 2023 (down 73.6%), KRW 17 billion in 2024 (up 73.8%) and KRW 16.6 billion in 2025 (down 2.1%).

Net income including non-controlling interests was KRW 36.6 billion, KRW 9.69 billion, KRW 16.1 billion and KRW 15.7 billion over the same years. The company attributed the 2025 profit decline to higher selling and administrative costs and a restructuring of its business, including the disposal of subsidiaries.

Legal costs are also a burden: payment fees including legal expenses reached KRW 61 billion in 2025, up about 13% from KRW 54.2 billion. Quarterly results moved from an operating profit of KRW 8.9 billion in Q3 2025 to an operating loss of KRW 3.69 billion in Q4 2025, a swing into the red.

Q1 2026 returned to operating profit of KRW 7.37 billion, while Q2 2026 revenue of KRW 68.7 billion (up 13.2% from the prior quarter) coincided with operating profit falling 35.4% to KRW 4.76 billion.

The company linked the Q2 decline to higher costs from scheduled plant maintenance and higher marketing and R&D spending on new products. Q3 2026 operating profit rebounded to KRW 15.5 billion, up 226.0% from the prior quarter.

Press reports put cost of sales at KRW 19.7 billion in Q3, down from KRW 27.6 billion in Q2, and SG&A at KRW 24.0 billion, down from KRW 36.3 billion, with the cost ratio falling from 40.2% to 33.2%.

Over the most recent four quarters, from Q4 2025 to Q3 2026, profit attributable to controlling shareholders totaled KRW 19.5 billion. Operating cash flow was KRW 26.2 billion in 2022, KRW 13.5 billion in 2023, KRW 36.6 billion in 2024 and KRW 61.4 billion in 2025, the highest of the four years.

05

Industry analysis

The global botulinum toxin market is still described as growing, but reports point to rising competition and possible price pressure. Industry commentary has flagged Medy-Tox's heavy reliance on a single product line as a medium-term issue.

The company says its premium toxin Coretox has strengthened its position in the Korean premium toxin market. Reports cited continued sales growth in Brazil, Thailand and Saudi Arabia. The next-generation product Neulux is expanding its list of approved countries across Europe and Asia.

As of June 2026 reporting, Medy-Tox had not yet entered the United States or China, the two largest markets for toxins, which was noted as a constraint on long-term growth. For fillers, the company says it is pursuing direct entry into the Chinese market.

A trade secret lawsuit against Daewoong Pharmaceutical, filed in 2017, has continued for a long period, and litigation with Hugel is also ongoing. Medy-Tox is shifting its global filler channel toward direct exports to internalize intermediary distribution margins.

Overseas toxin expansion and cost-efficiency gains are advancing at the same time, while legal expense burdens remain a variable when assessing its competitive position.

06

Outlook

The company has said it will concentrate its full capacity on achieving record annual revenue in 2026. Newbizu reached its 2026 annual sales target early, making it the first clear example of new-product growth.

For fillers, the company expects local supply in China to ramp up from Q4 2026 and overseas filler sales to visibly improve. Some domestic toxin shipments were pushed from Q3 into Q4, so how much of that volume is recognized in Q4 revenue is a point to watch.

Whether the shift to direct exports, which aims to internalize intermediary distribution margins, shows up in reported results is the next item to track. Neulux is widening its base of approved countries, and the dual-brand strategy with Meditoxin supports overseas toxin growth.

Legal costs continue to arise each quarter while litigation with Daewoong Pharmaceutical and Hugel is ongoing, making the trend in these costs a central variable for the profit outlook.

Reports said cumulative operating profit for January to September 2026, at KRW 27.7 billion, already exceeds the full-year operating profit of KRW 17 billion for 2025 and KRW 20.3 billion for 2024. The next annual business report for 2026 is the main checkpoint for how annual revenue and operating margin turn out.

07

Valuation

PER
24.1×
PBR
1.2×
ROE
4.6%
EPS
₩2,965
BPS
₩59,192
Dividend per share
₩1,200

Valuation can only be read by looking at the absolute level of earnings alongside legal cost variables. Profit attributable to controlling shareholders over the most recent four quarters, from Q4 2025 to Q3 2026, totaled KRW 19.5 billion, more than the FY2025 figure of KRW 16.6 billion.

Q4 2025 was a quarter with a loss attributable to controlling shareholders, so quarterly variation is large. Controlling shareholders' equity stood at KRW 451.8 billion at the end of 2025, and the price-to-book level sits in a range with a modest premium to net assets.

Because the operating margin fell from 23.9% in 2022 to 6.9% in 2025, reading the multiple depends on whether margin recovery holds over several quarters.

The narrowing gap between adjusted margin excluding legal costs and the reported margin, from 22 percentage points to 7 percentage points, is a factual change in the earnings structure.

In June 2026, a Korea Investment & Securities analyst said that, compared with peers in the sector, legal cost uncertainty and litigation risk leave limited room for value appreciation.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Overseas toxins emerging as a growth axis

Overseas toxin sales in Q3 2026 rose 17% year on year to KRW 20.9 billion. The dual-brand approach pairing Meditoxin and Neulux is being used to meet demand country by country, and Neulux is expanding its approved markets in Europe and Asia.

Lower cost ratios and SG&A lift the third quarter

Press reports put Q3 2026 cost of sales at KRW 19.7 billion, down from KRW 27.6 billion in Q2, and SG&A at KRW 24.0 billion, down from KRW 36.3 billion. As a result, the cost ratio fell from 40.2% to 33.2%. The company said higher plant utilization from expanded overseas approvals contributed to the improvement.

New products and filler restructuring as the next path

Newbizu, a fat-reduction injection and a 40th domestic new drug, has gained traction in Korea and reached its 2026 annual sales target early. Local supply of two Neuramis products, which received Chinese approval, is scheduled to start in earnest in Q4.

The company said the shift to direct exports and direct entry into the Chinese filler market should support a recovery in results.

09

Bear factors

Growing toxin concentration and filler decline

Botulinum toxins are becoming a larger share of revenue. Their share rose to 62% in Q1 2026 from 51% a year earlier, while other businesses accounted for only 12.4%. Filler sales fell temporarily again in Q3 2026 due to channel restructuring, so one of the two core lines remains under pressure.

Domestic toxin decline and shipment timing

Domestic toxin sales in Q3 2026 fell 17% year on year to KRW 14.6 billion. The company attributed part of the decline to shipments of some volume being pushed into Q4. How much of that volume is recognized in Q4 will shape how the domestic toxin trend is read. Coretox is selling steadily in Korea, but a broader recovery in domestic sales still needs confirmation.

Legal cost burden and the margin gap

Payment fees including legal costs reached KRW 61 billion in 2025, up about 13% from KRW 54.2 billion a year earlier. In Q3 2026 the adjusted margin excluding legal costs was 33% on the company's IR material, while the reported margin was about 26%, leaving a gap.

As long as litigation with Daewoong Pharmaceutical and Hugel continues, sizable legal costs will arise each quarter and constrain earnings stability.

10

Risk factors

Litigation and legal costs

Litigation with Daewoong Pharmaceutical over trade secrets and the dispute with Hugel are continuing, so legal costs arise every quarter. Payment fees including legal costs rose to KRW 61 billion in 2025. Depending on litigation outcomes, the cost path could change and widen the swings in profit.

Toxin dependence and price competition

With toxins at 62% of sales, changes in price or volume for a single product line feed directly into results. Competition and price pressure in the global toxin market are cited as possible risks.

Not yet being in the United States or China, the two largest toxin markets, is also flagged as a constraint on growth paths.

Earnings volatility and shipment timing

Q4 2025 swung to an operating loss of KRW 3.69 billion. In Q2 2026, revenue rose to KRW 68.7 billion, but operating profit fell to KRW 4.76 billion as higher costs from scheduled plant maintenance weighed. Quarterly results are sensitive to shipment timing and plant utilization, which makes them more volatile.

11

What to watch next

  1. Q4 2026

    The next checkpoints are whether local supply of the two Neuramis products in China ramps up and whether the domestic toxin volume delayed from Q3 is reflected in Q4 sales. Recovery in overseas filler sales is also in focus.

  2. By end-March 2027

    This is the deadline for the 2026 annual business report. Key items are whether annual revenue exceeds the KRW 247.3 billion recorded in 2025 and how the annual operating margin compares with 6.9% in 2025.

  3. Around May 2027

    This is the expected timing of the Q1 2027 preliminary results. The Q1 2026 preliminary results were disclosed on May 12, 2026. Points to check are whether operating profit holds near the Q1 2026 level of KRW 7.37 billion and whether the adjusted margin excluding legal costs keeps trending as it has.

12

Overall view

Medy-Tox's Q3 2026 can be summarized by two contrasting figures: revenue of KRW 59.3 billion, down 2.8% year on year, and operating profit of KRW 15.5 billion, up 74.5%. The profit gain came from lower cost ratios and SG&A, built on overseas toxin growth.

Domestic toxin sales fell to KRW 14.6 billion as shipments shifted, and filler sales declined temporarily due to channel restructuring. On an annual basis, revenue rose for three consecutive years to KRW 247.3 billion in 2025, but operating profit fell to KRW 17 billion and the operating margin narrowed to 6.9%.

Legal costs are a large cost factor, with payment fees including them reaching KRW 61 billion in 2025. Factors on the positive side include overseas toxin expansion, the early achievement of Newbizu's target, and improved cost structure.

On the negative side, toxin concentration, legal cost burdens and quarterly volatility stand out. The next checkpoints are the reflection of domestic toxin shipments and Neuramis supply in Q4 2026, and the annual results in the 2026 annual business report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. betanews.net
  2. inthenews.co.kr
  3. kr.investing.com
  4. asiatime.co.kr
  5. medicaldaily.co.kr
  6. healthfocus.co.kr
  7. ajunews.com
  8. seoul.co.kr
  9. m.etoday.co.kr
  10. m.sedaily.com
  11. asiatoday.co.kr
  12. dealsite.co.kr
  13. financialpost.co.kr
  14. m.news.nate.com
  15. fetv.co.kr
  16. joongangenews.com
  17. daily.hankooki.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis